Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs

Heart

Volumn 97, Issue 22, 2011, Pages 1834-1840

  Grimaldi Bensouda, Lamiae ^a,b   Rossignol, Michel ^c,d   Danchin, Nicolas ^e,f   Steg, P Gabriel ^g   Bessede, Gerard ^h   Ovize, Michel ^g   Cottin, Yves ⁱ   Autret Leca, Elisabeth ^j   Benichou, Jacques ^k,l   Abenhaim, Lucien ^m,n  

^a INSTITUT PASTEUR   (France)

^b LA SER   (France)

^c MCGILL UNIVERSITY   (Canada)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g INSERM   (France)

^h Centre Hospitalier de Gueret   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ DE TOURS   (France)

^k ROUEN UNIVERSITY HOSPITAL   (France)

^l INSERM U657   (France)

^m LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁿ LA SER Ltd   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALMINOPROFEN; ARYLPROPIONIC ACID DERIVATIVE; CELECOXIB; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PHENYLBUTAZONE; PIROXICAM; SULINDAC; TENOXICAM; TIAPROFENIC ACID;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DICLOFENAC; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FRANCE; HEART CONDUCTION SYSTEM; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 80055107432     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.222448     Document Type: Article

References (38)

1. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-21. (Pubitemid 28274844)
2. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366-70.
3. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81. (Pubitemid 40215729)
4. Fischer LM, Schlienger RG, Matter CM, et al. Current use of non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005;25:503-10. (Pubitemid 40471493)
5. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, et al. Non-steroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000-6. (Pubitemid 38808323)
6. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002;54:327-32.
7. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10. (Pubitemid 34522395)
8. Gislason GH, Jacobsen S, Rasmussen J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-13. (Pubitemid 44297231)
9. Hammad TA, Graham DJ, Staffa JA, et al. Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2008;17:315-21. (Pubitemid 351566346)
10. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27:1657-63. (Pubitemid 44025350)
11. Fosbøl EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85:190-7.
12. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
13. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4. (Pubitemid 36207477)
14. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
15. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-84. (Pubitemid 40638117)
16. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6. (Pubitemid 36241027)
17. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and nonselective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient not the drug class. Ann Rheum Dis 2005;64 (Suppl III):85.
18. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9.
19. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin nonsteroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004;43:985-90. (Pubitemid 38352976)
20. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
21. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44. (Pubitemid 44511610)
22. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986;315:417-23. (Pubitemid 16075605)
23. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902. (Pubitemid 10021186)
24. Steg PG, Goldberg RJ, Gore JM, et al. GRACE Investigators. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358-63.
25. Fox KA, Steg PG, Eagle KA, et al. GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-900. (Pubitemid 46707843)
26. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15. (Pubitemid 43121782)
27. Bueno H, Bardají A, Patrignani P, et al. Spanish Case-Control Study to Assess NSAID-Associated ACS Risk Investigators. Use of non-steroidal anti-inflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010;105:1102-6.
28. García Rodríguez LA, González-Pérez A, Bueno H, et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011;6:e16780.
29. van den Hondel KE, Eijgelsheim M, Ruiter R, et al. Effect of short-term NSAID use on echocardiographic parameters in elderly people: a population-based cohort study. Heart 2011;97:540-3.
30. Aneja A, Farkouh ME. Non-steroidal anti-inflammatory drugs and the heart. Heart 2011;97:517-18.
31. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16. (Pubitemid 26277950)
32. Grimaldi-Bensouda L, Rossignol M, Aubrun E, et al. PGRx Study Group. Agreement between patients' self-report and physicians' prescriptions on cardiovascular drug exposure: the PGRx database experience. Pharmacoepidemiol Drug Saf 2010;19:591-5.
33. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-90. (Pubitemid 37407794)
34. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23. (Pubitemid 34112540)
35. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
36. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-104. (Pubitemid 34522394)
37. Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with non-steroidal anti-inflammatory drugs. Stroke 2003;34:379-86.
38. Scheffold T, Kullmann S, Huge A, et al. Forschungsverbund Herz-Kreislauf in NRW (Research Consortium Heart and Circulation in North Rhine-Westphalia). Six sequence variants on chromosome 9p21.3 are associated with a positive family history of myocardial infarction: a multicenter registry. BMC Cardiovasc Disord 2011;11:9.